Sopharma AD (WSE:SPH)

Poland flag Poland · Delayed Price · Currency is PLN
12.75
-0.25 (-1.92%)
Sep 11, 2025, 7:15 PM CET
-1.92%
Market Cap2.98B
Revenue (ttm)5.23B
Net Income (ttm)222.10M
Shares Outn/a
EPS (ttm)0.44
PE Ratio13.40
Forward PEn/a
Dividend0.23 (1.80%)
Ex-Dividend DateJul 10, 2025
Volume2,082
Average Volumen/a
Open12.75
Previous Close12.75
Day's Range12.75 - 12.75
52-Week Range1.67 - 16.00
Beta-0.15
RSI51.65
Earnings DateAug 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices... [Read more]

Sector Healthcare
Founded 1933
Employees 5,599
Stock Exchange Warsaw Stock Exchange
Ticker Symbol SPH
Full Company Profile

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN Financial Statements

News

There is no news available yet.